Since our findings suggested that IGF1R and PTK2 synergistically augmented the aggressiveness of HCC mediated by BACH1, we speculated that the combination of IGF1R inhibitors and PTK2 inhibitors might elicit an enhanced therapeutic efficacy for HCC. The gene discussed is BACH1; the disease is hepatocellular carcinoma.